Identification of chromatin modifying mechanisms in human primary macrophages in an inflammatory model by Rooke, K, Kruidenier, L, Che, K, Mander, P, Swales, C, Prinjha, R, Oppermann, U

Identification of chromatin modifying mechanisms in inflammatory macrophages in rheumatoid arthritis by Rooke, K, Mander, P, Kruidenier, L, Martinez, F, Al-Mossawi, M, Bowness, P, Swales, C, Prinjha, R, Oppermann, U

Nogo-A and Nogo-66 receptor in multiple sclerosis and amyotrophic lateral sclerosis spinal cord and injured human peripheral nerves by Durrenberger, P, Facer, P, Casula, M, Prinjha, R, Moore, S, Woodhams, P, Bountra, C, Ravid, R, Birch, R, Anand, P

Inhibition of histone H3K27 demethylase selectively modulates inflammatory phenotypes of natural killer cells by Cribbs, A, Hookway, E, Wells, G, Lindow, M, Obad, S, Oerum, H, Prinjha, R, Athanasou, N, Sowman, A, Philpott, M, Penn, H, Soderstrom, K, Feldmann, M, Oppermann, U

Discovery and characterization of GSK2801, a selective chemical probe for the bromodomains BAZ2A and BAZ2B by Chen, P, Chaikuad, A, Bamborough, P, Bantscheff, M, Bountra, C, Chung, C, Fedorov, O, Grandi, P, Jung, D, Lesniak, R, Lindon, M, Müller, S, Philpott, M, Prinjha, R, Rogers, C, Selenski, C, Tallant, C, Werner, T, Willson, T, Knapp, S, Drewry, D

Structural analysis of human KDM5B guides histone demethylase inhibitor development. by Johansson, C, Velupillai, S, Tumber, A, Szykowska, A, Hookway, E, Nowak, R, Strain-Damerell, C, Gileadi, C, Philpott, M, Burgess-Brown, N, Wu, N, Kopec, J, Nuzzi, A, Steuber, H, Egner, U, Badock, V, Munro, S, LaThangue, N, Westaway, S, Brown, J, Athanasou, N, Prinjha, R, Brennan, P, Oppermann, U

Assessing histone demethylase inhibitors in cells: lessons learned by Hatch, S, Yapp, C, Montenegro, R, Savitsky, P, Gamble, V, Tumber, A, Ruda, G, Bavetsias, V, Fedorov, O, Atrash, B, Raynaud, F, Lanigan, R, Carmichael, L, Tomlin, K, Burke, R, Westway, S, Brown, J, Prinjha, R, Martinez, E, Oppermann, U, Schofield, C, Bountra, C, Kawamura, A, Blagg, J, Brennan, P, Rossanese, O, Müller, S

Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. by Chaidos, A, Caputo, V, Gouvedenou, K, Liu, B, Marigo, I, Chaudhry, M, Rotolo, A, Tough, D, Smithers, N, Bassil, A, Chapman, t, Harker, N, Barbash, O, Tummino, P, Al-Mahdi, N, Haynes, A, Cutler, L, Le, B, Rahemtulla, A, Roberts, I, Kleijnen, M, Witherington, J, Parr, N, Prinjha, R, Karadimitris, A

Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy by Picaud, S, Fedorov, O, Thanasopoulou, A, Leonards, K, Jones, K, Meier, J, Olzscha, H, Monteiro, O, Martin, S, Philpott, M, Tumber, A, Filippakopoulos, P, Yapp, C, Wells, C, Che, K, Bannister, A, Robson, S, Kumar, U, Parr, N, Lee, K, Lugo, D, Jeffrey, P, Taylor, S, Vecellio, M, Bountra, C, Brennan, P, O'Mahony, A, Velichko, S, Müller, S, Hay, D, Daniels, D, Urh, M, La Thangue, N, Kouzarides, T, Prinjha, R, Schwaller, J, Knapp, S

8-substituted pyrido[3,4-d]pyrimidin-4(3H)-one derivatives as potent, cell permeable, KDM4 (JMJD2) and KDM5 (JARID1) histone lysine demethylase inhibitors by Bavetsias, V, Lanigan, R, Ruda, G, Atrash, B, McLaughlin, M, Tumber, A, Mok, N, Le Bihan, Y, Dempster, S, Boxall, K, Jeganathan, F, Hatch, S, Savitsky, P, Velupillai, S, Krojer, T, England, K, Sejberg, J, Thai, C, Donovan, A, Pal, A, Scozzafava, G, Bennett, J, Kawamura, A, Johansson, C, Szykowska, A, Gileadi, C, Burgess-Brown, N, von Delft, F, Oppermann, U, Walters, Z, Shipley, J, Raynaud, F, Westaway, S, Prinjha, R, Fedorov, O, Burke, R, Schofield, C, Westwood, I, Bountra, C, Müller, S, van Montfort, R, Brennan, P, Blagg, J